Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TH-Z835 is a selective inhibitor for the KRAS (G12D) mutation, demonstrating an inhibitory concentration (IC50) of 1.6 μM. It effectively hampers both mantGMPPNP/GPPNP and GPPNP/mantGMPPNP exchanges [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | TH-Z835 is a selective inhibitor for the KRAS (G12D) mutation, demonstrating an inhibitory concentration (IC50) of 1.6 μM. It effectively hampers both mantGMPPNP/GPPNP and GPPNP/mantGMPPNP exchanges [1]. |
Targets&IC50 | KRAS(G12D):1.6 μM |
In vitro | TH-Z835 reduces pERK levels in PANC-1 cells with an IC50 value less than 2.5 μM [1]. Additionally, TH-Z835 exhibits antiproliferative effects in various non-G12D mutant cancer cell lines, including 4T1 (KRAS(WT)), MIA PaCa-2 (KRAS(G12C)), CFPAC-1 (KRAS(G12V)), and HCT116 (KRAS(G13D)), by decreasing pERK and pAKT levels and inducing apoptosis, indicating off-target effects [1]. |
In vivo | TH-Z835 (10mg/kg; intraperitoneal injection) reduces tumor volume in a C57BL/6 mouse model. In vivo, TH-Z835 induces apoptosis and inhibits MAPK signaling [1]. |
Molecular Weight | 498.66 |
Formula | C30H38N6O |
CAS No. | 2766209-50-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
TH-Z835 2766209-50-9 GPCR/G Protein MAPK Ras inhibitor inhibit